CLINICAL STUDY: PEDIATRIC CARDIOLOGY
Redilation of endovascular stents in congenital heart disease: factors implicated in the development of restenosis and neointimal proliferation
Colin J. McMahon, MB, BAO, BCh, MRCP*,
Howaida G. El-Said, MD, PhD*,
Ronald G. Grifka, MD, FACC*,
J. Kennard Fraley, MPH ,
Michael R. Nihill, MD, FACC* and
Charles E. Mullins, MD, FACC*
* LillieFrank Abercrombie Division of Pediatric Cardiology, Texas Children’s Hospital and Baylor College of Medicine, Houston, USA
Children’s Nutrition Research Center, Houston, Texas, USA
Manuscript received January 10, 2001;
revised manuscript received April 19, 2001,
accepted April 27, 2001.
Reprint requests and correspondence: Dr. Howaida G. El-Said, Division of Pediatric Cardiology, Texas Children’s Hospital, 6621 Fannin, MC 2-2280, Houston, Texas 77030
hgelsaid{at}texaschildrenshospital.org
OBJECTIVES
We sought to determine the incidence of and risk factors for the development of restenosis and neointimal proliferation after endovascular stent implantation for congenital heart disease (CHD).
BACKGROUND
Risk factors for the development of restenosis and neointimal proliferation are poorly understood.
METHODS
This was a retrospective review of patients who underwent endovascular stent redilation between September 1989 and February 2000.
RESULTS
Of 368 patients who had 752 stents implanted, 220 were recatheterized. Of those 220 patients, 103 underwent stent redilation. Patients were classified into three groups: 1) those with pulmonary artery stenosis (n = 94), tetralogy of Fallot/pulmonary atresia (n = 72), congenital branch pulmonary stenosis (n = 9), status post-Fontan operation (n = 6), status post-arterial switch operation (n = 7); 2) those with iliofemoral venous obstruction (n = 6); and 3) those with miscellaneous disorders (n = 3). The patients’ median age was 9.9 years (range 0.5 to 39.8); their mean follow-up duration was 3.8 years (range 0.1 to 10). Indications for stent redilation included somatic growth (n = 67), serial dilation (n = 27) and development of neointimal proliferation or restenosis, or both (n = 9). There was a low incidence of neointimal proliferation (1.8%) and restenosis (2%). There were no deaths. Complications included pulmonary edema (n = 1), hemoptysis (n = 1) and contralateral stent compression (n = 2).
CONCLUSIONS
Redilation or further dilation of endovascular stents for CHD is effective as late as 10 years. The risk of neointimal proliferation (1.8%) and restenosis (2%) is low and possibly avoidable. Awareness of specific risk factors and modification of the stent implantation technique, including avoidance of minimal stent overlap and sharp angulation of the stent to the vessel wall and avoidance of overdilation, have helped to reduce the incidence of restenosis.
|
Abbreviations and Acronyms
| | ASO | = arterial switch operation | | CBPS | = congenital branch pulmonary stenosis | | CHD | = congenital heart disease | | FA | = femoral artery | | IVC | = inferior vena cava | | PA | = pulmonary atresia | | RV | = right ventricle or ventricular | | SVC | = superior vena cava | | TOF | = tetralogy of Fallot | | TR | = tricuspid regurgitation |
|
This article has been cited by other articles:
|
|
|
|
 
J. Maglione, L. Bergersen, J. E. Lock, and D. B. McElhinney
Ultra-High-Pressure Balloon Angioplasty for Treatment of Resistant Stenoses Within or Adjacent to Previously Implanted Pulmonary Arterial Stents
Circ Cardiovasc Interv,
February 1, 2009;
2(1):
52 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al.
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease) Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
December 2, 2008;
52(23):
e143 - e263.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al.
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Circulation,
December 2, 2008;
118(23):
e714 - e833.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Eichhorn, C. Jourdan, S. L. Hill, S. V. Raman, J. P. Cheatham, and F. R. Long
CT of Pediatric Vascular Stents Used to Treat Congenital Heart Disease
Am. J. Roentgenol.,
May 1, 2008;
190(5):
1241 - 1246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tzifa, A. C. Marshall, D. B. McElhinney, J. E. Lock, and R. L. Geggel
Endovascular Treatment for Superior Vena Cava Occlusion or Obstruction in a Pediatric and Young Adult Population: A 22-Year Experience
J. Am. Coll. Cardiol.,
March 6, 2007;
49(9):
1003 - 1009.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. van Gameren, M. Witsenburg, J. J.M. Takkenberg, D. Boshoff, L. Mertens, A. M. van Oort, D. de Wolf, M. Freund, N. Sreeram, R. Bokenkamp, et al.
Early complications of stenting in patients with congenital heart disease: a multicentre study
Eur. Heart J.,
November 2, 2006;
27(22):
2709 - 2715.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chessa, M. Carrozza, G. Butera, L. Piazza, D. G. Negura, C. Bussadori, E. Bossone, A. Giamberti, and M. Carminati
Results and mid-long-term follow-up of stent implantation for native and recurrent coarctation of the aorta
Eur. Heart J.,
December 2, 2005;
26(24):
2728 - 2732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Hwang, P.-C. Lee, Y.-C. Fu, S.-L. Jan, C.-C. Kao, P.-Y. Wang, C.-H. Lien, Z.-C. Weng, and C. C. L. Meng
Transcatheter Implantation of Intravascular Stents for Postoperative Residual Stenosis of Peripheral Pulmonary Artery Stenosis
Angiology,
September 1, 2004;
55(5):
493 - 498.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C Duke, E Rosenthal, and S A Qureshi
The efficacy and safety of stent redilatation in congenital heart disease
Heart,
August 1, 2003;
89(8):
905 - 912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C J McMahon, C E Mullins, and H G El Said
Intrastent sonotherapy in pulmonary vein restenosis: a new treatment for a recalcitrant problem
Heart,
February 1, 2003;
89(2):
e6 - 6.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C E Mullins
Vessel restenosis versus "streamlining"
Heart,
December 1, 2002;
88(5):
445 - 446.
[Full Text]
[PDF]
|
|
|
|
